Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology · 2026
Clinical efficacy of Jiawei Yinchenhao decoction combined with ursodeoxycholic acid and probiotics in the management of nonalcoholic fatty liver disease.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Chen Dong, Li Xinyu, Fu Jinghao, Ma Yaohan, Jiang Hanyue, Li Qiang
Аннотация
OBJECTIVE: The study focused on evaluating the clinical effectiveness of Jiawei Yinchenhao decoction (JWYCH) combined with ursodeoxycholic acid (UDCA) and probiotics in the treatment of nonalcoholic fatty liver disease (NAFLD).
METHODS: Patients with NAFLD were divided into an observation group (JWYCH + UDCA + probiotics) and a control group (UDCA + probiotics). Clinical efficacy, liver function, blood lipids, oxidative stress indicators, inflammatory cytokines, gut microbiota composition, and adverse events were assessed before and after 4 weeks of treatment.
RESULTS: The observation group demonstrated a significantly higher clinical effective rate (90.00 %) compared to the control group (71.67 %) (P < 0.05). Both groups showed improved gut flora (increased Bifidobacterium and Lactobacillus, decreased Escherichia coli and Enterococcus), reduced liver enzymes (ALT, AST), bilirubin (TBil), and lipid levels (TC, LDL-C), and attenuated oxidative stress (lower MDA, higher GSH-Px and SOD) and inflammatory markers (TGF-β, TNF-α, IL-8); the observation group exhibited greater improvements across all indicators than the control group (P < 0.05). Adverse reactions were minimal and comparable between groups.
CONCLUSION: JWYCH combined with UDCA and probiotics provides superior therapeutic benefits for NAFLD by improving liver function, modulating intestinal microbiota, reducing inflammation and oxidative stress, and enhancing lipid metabolism, with good safety. This integrated approach holds promise for broader clinical application.
METHODS: Patients with NAFLD were divided into an observation group (JWYCH + UDCA + probiotics) and a control group (UDCA + probiotics). Clinical efficacy, liver function, blood lipids, oxidative stress indicators, inflammatory cytokines, gut microbiota composition, and adverse events were assessed before and after 4 weeks of treatment.
RESULTS: The observation group demonstrated a significantly higher clinical effective rate (90.00 %) compared to the control group (71.67 %) (P < 0.05). Both groups showed improved gut flora (increased Bifidobacterium and Lactobacillus, decreased Escherichia coli and Enterococcus), reduced liver enzymes (ALT, AST), bilirubin (TBil), and lipid levels (TC, LDL-C), and attenuated oxidative stress (lower MDA, higher GSH-Px and SOD) and inflammatory markers (TGF-β, TNF-α, IL-8); the observation group exhibited greater improvements across all indicators than the control group (P < 0.05). Adverse reactions were minimal and comparable between groups.
CONCLUSION: JWYCH combined with UDCA and probiotics provides superior therapeutic benefits for NAFLD by improving liver function, modulating intestinal microbiota, reducing inflammation and oxidative stress, and enhancing lipid metabolism, with good safety. This integrated approach holds promise for broader clinical application.